visitante ::
identificación
|
|||||||||||||||
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español |
Página principal > Artículos > Artículos publicados > Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers |
Fecha: | 2022 |
Resumen: | Objective: This study was undertaken to evaluate whether the feedback-related negativity (FRN)-a neurophysiological marker of incentive processing-can be used to predict the development of impulse control disorders (ICDs) in Parkinson disease (PD). Methods: The longitudinal cohort consisted of consecutive nondemented PD patients with no ICD history. We recorded FRN signals while they performed a gambling task. We calculated the mean amplitude difference between losses and gains (FRNdiff) to be used as a predictor of future ICD development. We performed prospective biannual follow-up assessments for 30 months to detect incident ICDs. Finally, we evaluated how basal FRNdiff was associated with posterior development of ICDs using survival models. Results: Between October 7, 2015 and December 16, 2016, we screened 120 patients. Among them, 94 patients performed the gambling and 92 completed the follow-up. Eighteen patients developed ICDs during follow-up, whereas 74 remained free of ICDs. Baseline FRNdiff was greater in patients who developed ICDs than in those who did not (−2. 33μV vs −0. 84μV, p = 0. 001). No other significant baseline differences were found. The FRNdiff was significantly associated with ICD development in the survival models both when not adjusted (hazard ratio [HR] = 0. 73, 95% confidence interval [CI] = 0. 58-0. 91, p = 0. 006) and when controlling for dopamine replacement therapy, sex, and age (HR = 0. 74, 95% CI = 0. 55-0. 97, p = 0. 035). None of the impulsivity measures evaluated was related to ICD development. Interpretation: Reward-processing differences measured by FRN signals precede ICD development in PD. This neurophysiological marker permits identification of patients with high risk of ICD development. ANN NEUROL 2022;92:974-984. |
Ayudas: | Instituto de Salud Carlos III PI15/00962 Instituto de Salud Carlos III PI18/01717 Instituto de Salud Carlos III JR20/00007 |
Nota: | Altres ajuts: Fundació la Marató de TV3 (2014/U/477, 20142910); Fondo Europeo de Desarrollo Regional (FEDER); Pla Estratègic de Recerca i Innovació (SLT008/18); CERCA (CEntres de Recerca de Catalunya); CIBERNED (Centro de Investigación Biomédica en Red de enfermedades NEuroDegenerativas). |
Derechos: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
Lengua: | Anglès |
Documento: | Article ; recerca ; Versió publicada |
Materia: | Biomarkers ; Disruptive, Impulse Control, and Conduct Disorders ; Dopamine Agonists ; Humans ; Motivation ; Parkinson Disease ; Prospective Studies |
Publicado en: | Annals of neurology, Vol. 92 Núm. 6 (december 2022) , p. 974-984, ISSN 1531-8249 |
11 p, 715.9 KB |